New Vaccine Gives Brain Cancer Patients Hope of Longer Survival
Traditionally, vaccines have been used as a way to prevent many diseases, such as the childhood vaccines used to prevent measles. However, scientists are now developing therapeutic vaccines that can be given to cancer patients in order to slow or reverse the progression of the malignancy. One such vaccine was recently developed in Germany and the results offer cautious hope for patients with deadly brain tumors.
In a study that was published in the Nature journal, the scientists described their small trial that involved 33 patients diagnosed with high-grade astrocytomas. These tumors usually recur and progress to a level that is untreatable, resulting in death.
Michael Platten, one of the study leads based at the German Cancer Research Center, explains that they gave these patients the vaccine and followed them up for eight years. 66% of those study participants were still alive and 42% hadn’t experienced cancer recurrence. Typically, nearly all patients die within five years after getting this diagnosis.
These findings were surprising and encouraging since they bucked the normal trajectory of the way this particular brain cancer presents.
The particular vaccine they developed trained the immune system to identify the specific neoepitope molecule that drives tumor progression. By training immune cells to recognize this protein, the body was able to attack the tumor and slow its growth.
The researchers warn that the scientific community and patients shouldn’t be carried away by these results since the study population was a small one and the results may not hold up in a larger study.
They plan to undertake a larger clinical study involving at least 200 patients, and this planned study is scheduled to commence in March 2027. That study will investigate whether the findings are equally impressive in a larger cohort of patients and the findings are expected about eight years later.
The plan is to also look into whether giving the patients booster shots can sustain the initial encouraging results, or whether the initial treatment is sufficient. Adverse events resulting from the vaccine will also be analyzed and possible remedies will be looked into.
For patients with this cancer, there is reason to hope because existing treatment approaches, such as surgery and radiotherapy haven’t proved to be very successful in halting disease recurrence. As the team painstakingly takes their innovation through the clinical development process, other efforts by for-profit firms like CNS Pharmaceuticals Inc. (NASDAQ: CNSP) are also moving along at an encouraging pace.
Consequently, there is reason to hope that astrocytomas could one day become treatable just like many other cancers afflicting the central nervous system.
Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer
Traditionally, vaccines have been used as a way to prevent many diseases, such as the childhood vaccines used to prevent measles. However, scientists are now developing therapeutic vaccines that can be given to cancer patients in order to slow or reverse the progression of the malignancy. One such vaccine was recently developed in Germany and the results offer cautious hope for patients with deadly brain tumors.
In a study that was published in the Nature journal, the scientists described their small trial that involved 33 patients diagnosed with high-grade astrocytomas. These tumors usually recur and progress to a level that is untreatable, resulting in death.
Michael Platten, one of the study leads based at the German Cancer Research Center, explains that they gave these patients the vaccine and followed them up for eight years. 66% of those study participants were still alive and 42% hadn’t experienced cancer recurrence. Typically, nearly all patients die within five years after getting this diagnosis.
These findings were surprising and encouraging since they bucked the normal trajectory of the way this particular brain cancer presents.
The particular vaccine they developed trained the immune system to identify the specific neoepitope molecule that drives tumor progression. By training immune cells to recognize this protein, the body was able to attack the tumor and slow its growth.
The researchers warn that the scientific community and patients shouldn’t be carried away by these results since the study population was a small one and the results may not hold up in a larger study.
They plan to undertake a larger clinical study involving at least 200 patients, and this planned study is scheduled to commence in March 2027. That study will investigate whether the findings are equally impressive in a larger cohort of patients and the findings are expected about eight years later.
The plan is to also look into whether giving the patients booster shots can sustain the initial encouraging results, or whether the initial treatment is sufficient. Adverse events resulting from the vaccine will also be analyzed and possible remedies will be looked into.
For patients with this cancer, there is reason to hope because existing treatment approaches, such as surgery and radiotherapy haven’t proved to be very successful in halting disease recurrence. As the team painstakingly takes their innovation through the clinical development process, other efforts by for-profit firms like CNS Pharmaceuticals Inc. (NASDAQ: CNSP) are also moving along at an encouraging pace.
Consequently, there is reason to hope that astrocytomas could one day become treatable just like many other cancers afflicting the central nervous system.
Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer
